249 related articles for article (PubMed ID: 28651817)
1. Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer.
Markowska A; Sajdak S; Markowska J; Huczyński A
Eur J Med Chem; 2017 Dec; 142():87-94. PubMed ID: 28651817
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer stem cells: A target for oncological therapy.
Markowska A; Sajdak S; Huczyński A; Rehlis S; Markowska J
Adv Clin Exp Med; 2018 Jul; 27(7):1017-1020. PubMed ID: 29938937
[TBL] [Abstract][Full Text] [Related]
3. Salinomycin reduces stemness and induces apoptosis on human ovarian cancer stem cell.
Lee HG; Shin SJ; Chung HW; Kwon SH; Cha SD; Lee JE; Cho CH
J Gynecol Oncol; 2017 Mar; 28(2):e14. PubMed ID: 27894167
[TBL] [Abstract][Full Text] [Related]
4. Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.
Loizzi V; Del Vecchio V; Gargano G; De Liso M; Kardashi A; Naglieri E; Resta L; Cicinelli E; Cormio G
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28906427
[TBL] [Abstract][Full Text] [Related]
5. The role of Notch signalling in ovarian angiogenesis.
Xie Q; Cheng Z; Chen X; Lobe CG; Liu J
J Ovarian Res; 2017 Mar; 10(1):13. PubMed ID: 28284219
[TBL] [Abstract][Full Text] [Related]
6. The inhibitory effect of hypoxic cytotoxin on the expansion of cancer stem cells in ovarian cancer.
Nozawa-Suzuki N; Nagasawa H; Ohnishi K; Morishige K
Biochem Biophys Res Commun; 2015 Feb; 457(4):706-11. PubMed ID: 25619133
[TBL] [Abstract][Full Text] [Related]
7. The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer.
Gubbi A; Kendrick JE; Finkler NJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1105-13. PubMed ID: 25189201
[TBL] [Abstract][Full Text] [Related]
8. Overview of anti-angiogenic agents in development for ovarian cancer.
Burger RA
Gynecol Oncol; 2011 Apr; 121(1):230-8. PubMed ID: 21215996
[TBL] [Abstract][Full Text] [Related]
9. Metformin targets ovarian cancer stem cells in vitro and in vivo.
Shank JJ; Yang K; Ghannam J; Cabrera L; Johnston CJ; Reynolds RK; Buckanovich RJ
Gynecol Oncol; 2012 Nov; 127(2):390-7. PubMed ID: 22864111
[TBL] [Abstract][Full Text] [Related]
10. Pazopanib in ovarian cancer.
McLachlan J; Banerjee S
Expert Rev Anticancer Ther; 2015; 15(9):995-1005. PubMed ID: 26296187
[TBL] [Abstract][Full Text] [Related]
11. Angiogenesis: a promising therapeutic target for ovarian cancer.
Bamias A; Pignata S; Pujade-Lauraine E
Crit Rev Oncol Hematol; 2012 Dec; 84(3):314-26. PubMed ID: 22575381
[TBL] [Abstract][Full Text] [Related]
12. State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer.
Singh N; Badrun D; Ghatage P
Expert Opin Pharmacother; 2020 Sep; 21(13):1579-1590. PubMed ID: 32552175
[TBL] [Abstract][Full Text] [Related]
13. [Characterization of chosen pro-angiogenic factors and anti-angiogenic therapies in ovarian cancer].
Wiśniewski K; Pawłowska A; Bobiński M; Okła K; Kotarski J; Wertel I
Wiad Lek; 2018; 71(8):1603-1607. PubMed ID: 30684347
[TBL] [Abstract][Full Text] [Related]
14. Salinomycin as a drug for targeting human cancer stem cells.
Naujokat C; Steinhart R
J Biomed Biotechnol; 2012; 2012():950658. PubMed ID: 23251084
[TBL] [Abstract][Full Text] [Related]
15. Voice disorders induced by bevacizumab administration in an ovarian cancer patient: an underestimated and rare toxicity.
Kountourakis P; Antoniou G; Papadimitriou K; Vassiliou V; Syrigos D; Philippou M; Papamichael D
Hematol Oncol Stem Cell Ther; 2014 Sep; 7(3):123-4. PubMed ID: 25066794
[No Abstract] [Full Text] [Related]
16. Specific cell targeting with APRPG conjugated PEG-PLGA nanoparticles for treating ovarian cancer.
Wang Y; Liu P; Duan Y; Yin X; Wang Q; Liu X; Wang X; Zhou J; Wang W; Qiu L; Di W
Biomaterials; 2014 Jan; 35(3):983-92. PubMed ID: 24176193
[TBL] [Abstract][Full Text] [Related]
17. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment.
Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P
Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197
[TBL] [Abstract][Full Text] [Related]
18. Cancer stem cells contribute to angiogenesis and lymphangiogenesis in serous adenocarcinoma of the ovary.
Krishnapriya S; Sidhanth C; Manasa P; Sneha S; Bindhya S; Nagare RP; Ramachandran B; Vishwanathan P; Murhekar K; Shirley S; Ganesan TS
Angiogenesis; 2019 Aug; 22(3):441-455. PubMed ID: 31161471
[TBL] [Abstract][Full Text] [Related]
19. Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression.
Erices R; Cubillos S; Aravena R; Santoro F; Marquez M; Orellana R; Ramírez C; González P; Fuenzalida P; Bravo ML; Oliva B; Kato S; Ibañez C; Brañes J; Bravo E; Alonso C; García K; Arab C; Torres VA; Godoy AS; Pereira J; Bustos G; Cardenas JC; Cuello MA; Owen GI
Oncotarget; 2017 Mar; 8(13):20865-20880. PubMed ID: 28209916
[TBL] [Abstract][Full Text] [Related]
20. Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.
Tomao F; Papa A; Rossi L; Caruso D; Zoratto F; Benedetti Panici P; Tomao S
Expert Opin Investig Drugs; 2014 Jan; 23(1):37-53. PubMed ID: 24111925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
